

## AMENDMENTS TO THE CLAIMS

Claim 1. (Previously presented) The isolated peptide sequence GGIGDGG (SEQ ID NO:2).

Claim 2. (Currently amended) An angiogenic composition comprising the isolated peptide sequence GGIGDGG (SEQ ID NO:2); and at least one angiogenic peptide ~~other than said peptide selected from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- $\alpha$ ), transforming growth factor-beta (TGF- $\beta$ ), and tumor necrosis factor-alpha (TNF- $\alpha$ ).~~

Claim 3. (Canceled)

Claim 4. (Currently amended) The angiogenic composition of claim 2 wherein at least one said ~~other at least one~~ angiogenic peptide is a recombinant angiogenic peptide.

Claim 5. (Currently amended) A composition that is active for promoting cell migration and/or angiogenesis under cell growth promoting conditions, the composition comprising the isolated peptide sequence GGIGDGG (SEQ ID NO:2); and a matrix material.

Claim 6. (Previously presented) The composition of claim 5, further comprising a pharmacologically acceptable carrier.

Claims 7-19. (Cancelled)

Claim 20. (Currently amended) The angiogenic composition of claim 2 wherein said ~~other~~ at least one angiogenic peptide comprises bone-derived angiogenic proteins (BDAPs).

Claim 21. (Currently amended) The angiogenic composition of claim 2 wherein said ~~other~~ at least one angiogenic peptide comprises vascular endothelial cell growth factor (VEGF).

Claim 22. (Canceled)

Claim 23. (Previously presented) The composition of claim 2, further comprising a pharmacologically acceptable carrier.

Claim 24. (Previously presented) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 25. (Previously presented) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 26. (Previously presented) The composition of claim 2, wherein the composition is an injectable solution.

Claim 27. (Previously presented) The composition of claim 23, wherein the composition further comprises polyvinylpyrrolidinone.

Claim 28. (Previously presented) The composition of claim 23, wherein the composition further comprises hydrochloric acid.

Claim 29. (Currently amended) The angiogenic composition of claim 5, further comprising at least one angiogenic peptide ~~other than said at least one peptide~~ selected from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- $\alpha$ ), transforming growth factor-beta (TGF- $\beta$ ), and tumor necrosis factor-alpha (TNF- $\alpha$ ).

Claim 30. (Canceled)

Claim 31. (Previously presented) The angiogenic composition of claim 29 wherein said at least one angiogenic peptide comprises bone-derived angiogenic proteins (BDAPs).

Claim 32. (Previously presented) The angiogenic composition of claim 29 wherein said at least one angiogenic peptide comprises vascular endothelial cell growth factor (VEGF).

Claim 33. (Canceled)

Claim 34. (Previously presented) The composition of claim 5, further comprising a pharmacologically acceptable carrier.

Claim 35. (Previously presented) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 36. (Previously presented) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 37. (Previously presented) The composition of claim 5, wherein the composition is an injectable solution.

Claim 38. (Previously presented) The composition of claim 37, wherein the composition further comprises polyvinylpyrrolidinone.

Claim 39. (Previously presented) The composition of claim 37, wherein composition further comprises hydrochloric acid.

Claim 40. (Previously presented) The angiogenic composition of claim 5 wherein said matrix comprises a cell growth promoting matrix.